Juvenescence Appoints Eileen Jennings-Brown as CTO, Expands UAE Operations
Juvenescence, a clinical-stage AI-enabled biotech company, has appointed Eileen Jennings-Brown as Chief Technology Officer and established new research offices at Masdar City in Abu Dhabi to advance its longevity therapeutics pipeline.
Juvenescence Limited, a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan, announced the appointment of Eileen Jennings-Brown as Chief Technology Officer and a significant expansion of its operations in the United Arab Emirates through the establishment of new research offices at Masdar City, Abu Dhabi's rapidly growing life sciences and biotechnology hub.
Jennings-Brown is a highly regarded technology leader with more than 25 years of experience across life sciences, research and industry. She has held senior roles in internationally focused organizations, including serving as Chief Information Officer at Exscientia, an AI-driven precision medicine company acquired by Recursion in 2024. She also provided senior technology leadership at the Wellcome Trust, where she led the organization's technology strategy and large-scale digital transformation initiatives.
Her appointment coincides with Juvenescence's strategic expansion into the UAE, building upon the company's investment from M42, announced in April 2025, and reinforces the company's commitment to supporting the UAE's vision to build a leadership position in next-generation drug development. As CTO, Jennings-Brown will spearhead Juvenescence's global AI, data and technology strategy – critical to empowering Juvenescence's growing team of scientists and accelerating and advancing a pipeline of therapeutics that target fundamental aging mechanisms.
The Chief Technology Officer commented that Juvenescence offers a unique opportunity to combine technical expertise and experience in the scientific research industry and data-driven precision medicine with the emerging field of longevity. The Chief Executive Officer stated that Jennings-Brown brings exceptional expertise in building and scaling AI-driven technology platforms in biotech, having led technology transformation at Exscientia. Her deep understanding of how to harness computational power for drug discovery, combined with her track record of building world-class technical teams, will be instrumental as the company expands its JuvAI platform capabilities in the UAE and leverages the extraordinary data resources.
The partnership with Masdar City positions Juvenescence at the heart of the UAE's rapidly developing life sciences ecosystem. Masdar City's life science cluster offers world-class infrastructure, proximity to leading regional research institutions, government-backed initiatives from the Abu Dhabi Department of Health and the Abu Dhabi Investment Office, and access to a growing community of biotech and healthtech companies. This cluster provides unparalleled opportunities for collaboration, innovation and growth.
Juvenescence will look to build out facilities at Masdar City to feature an Advanced AI Drug Discovery Laboratory housing the company's proprietary JuvAI platform, which spans the entire drug discovery process from target selection to clinical trials, alongside collaboration spaces designed to facilitate partnerships with local and international research institutions.
Juvenescence is embedding in the UAE by hiring top talent, exploring opportunities to bring therapeutic assets to the region, and engaging with regulatory authorities on potential clinical studies in the region. The company is working closely with the regulatory authorities to conduct clinical studies in the region and work with the Abu Dhabi Department of Health to unlock insights from the world's largest genomic dataset (800,000+ whole genomes) through the Emirati Genome Project, as well as the UAE's comprehensive healthcare infrastructure.